Hostname: page-component-84b7d79bbc-tsvsl Total loading time: 0 Render date: 2024-07-30T19:43:51.804Z Has data issue: false hasContentIssue false
  • English
  • Français

Suicidality during neuromodulation in the elderly depressed: study design

Published online by Cambridge University Press:  01 September 2022

A. Van Daele ,
D. Zeeuws  and
C. Baeken
A. Van Daele
Affiliation:
Vrije Universiteit Brussel, Faculty Of Medicine And Pharmacy, Jette, Belgium
D. Zeeuws*
Affiliation:
Vrije Universiteit Brussel, Faculty Of Medicine And Pharmacy, Jette, Belgium University Hospital Brussels, Department Of Psychiatry, Jette, Belgium Vrije Universiteit Brussel, Center For Neurosciences (c4n), Jette, Belgium
C. Baeken
Affiliation:
Vrije Universiteit Brussel, Faculty Of Medicine And Pharmacy, Jette, Belgium University Hospital Brussels, Department Of Psychiatry, Jette, Belgium Vrije Universiteit Brussel, Center For Neurosciences (c4n), Jette, Belgium Ghent University, Psychiatry, Gent, Belgium Eindhoven University of Technology, Department Of Electrical Engineering, Eindhoven, Netherlands
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Late life depression is a major global health issue, with an estimated 7% of older adults suffering from this mental disorder. Depression is one of the most important predictors for suicide in the elderly. However, it is often difficult to recognize and manage, making treatment-resistance a common occurrence. Treatment-resistant depression itself is also a known risk factor for suicide. Recently, non-invasive neuromodulation techniques have been used as a new treatment for depression and suicidality with promising results.

Objectives

This study aims to investigate the effect of adTMS (accelerated deep Transcranial Magnetic Stimulation) and tDCS (transcranial Direct Current Stimulation) on the suicidality of elderly, therapy-resistant depressed patients. The hypothesis is that suicidal ideation and risk of suicide will decrease after a treatment with adTMS and tDCS.

Methods

In this randomized double-blinded sham-controlled clinical trial, geriatric therapy-resistant depressive patients will receive adTMS treatment (See: Figure 1). Suicidality will be assessed before and after the active or sham treatment, through the Columbia Suicide Severity Rating Scale (C-SSRS) and Beck Scale for Suicide Ideation (BSI). After one week of rest, all patients will receive an at-home tDCS treatment for 3 weeks. Likewise, the suicide risk will be estimated before and after the tDCS. During the screening period, the severity of the patients’ depressive symptoms will be determined by using the 17-item Hamilton Depression Rating Scale (HDRS-17). In total, the trial will last for 5 weeks, and suicidality will be examined at five different time points (during screening, at T0, T1, T2 and T3).

Results

Not applicable

Conclusions

Not applicable

Disclosure

No significant relationships.

Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S736 - S737
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.